Best Myeloma podcasts we could find (Updated March 2019)
Related podcasts: Cancer Health and Well-Being Multiple Myeloma Research Health Medicine 090993 Oncologist Cancercast Weill Prostate Cancer Myeloma Treatment Md Anderson Mpatient Myeloma Radio Myeloma Crowd Mpatient Immunotherapy Breakthroughs Cancer Lymphoma Leukemia Myeloma Battling Beating Survival Survivorship  
Myeloma public [search 0]
×
Join millions of Player FM users today to get Myeloma news and insights whenever you like, even when you're offline. Podcast smarter with the podcast app that refuses to compromise … it's free and easy.
Podcast smarter! Player FM is free and easy.
show episodes
 
Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
 
C
CureTalks
Monthly
 
CureTalks features leading medical experts in conversation with a panel of patients/advocates about latest research and treatments under development.
 
This program provides people diagnosed with multiple myeloma - as well as their caregivers, family, and friends - with practical tools you can use in your daily life as you deal with your cancer diagnosis and treatment.
 
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
 
A dynamic program devoted to battling and beating cancer of all types, with a particular emphasis on lymphoma, leukemia, and myeloma. Guests include doctors, survivors, patients, caregivers, and individuals providing information and resources for people impacted by cancer.
 
C
CancerCast
Monthly
 
New scientific developments are transforming the future of cancer treatment and care. Hosted by world-renowned hematologist and medical oncologist Dr. John Leonard, CancerCast is your window into research breakthroughs, innovative therapies and honest accounts of living with and beyond cancer. Questions or suggestions? Email us at cancercast@med.cornell.edu.
 
O
OT Broadcast News
Monthly
 
Audio-reports and interviews done in collaboration with Audio Medica and its founding Editor Peter Goodwin. Audio Medica's Audio Journal of Oncology has been bringing lively listen-in shows to members of the cancer care team in various audio formats since 1992.Scientific Editors are George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on t ...
 
Loading …
show series
 
Optimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression
 
The current state of myeloma therapy, plus the novel agents that may be next in line for FDA approval. Guest: Adriana Rossi, MD, Associate Director of the Myeloma Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Pr ...…
 
Eating disorders (ED) are serious and sometimes fatal illnesses that cause the sufferers to become obsessed with food, body weight and shape, and severely disturb their eating behaviour. Common eating disorders include binge eating disorder, bulimia nervosa, and anorexia nervosa. Recent research around the neurobiology of eating disorders has c ...…
 
Dr. David Fajgenbaum was diagnosed with a rare disorder that killed 35% of patients within five years of diagnosis. Dr. Fajgenbaum realised that he would have to lead the charge against his rare condition and we are talking to this young doctor about his incredible journey unraveling Castleman Disease. Castleman Disease is a rare disease of lym ...…
 
Is There a Cardio-Oncologist in the House? Managing Risk for VTE and Stroke Due to AF in Patients With Cancer
 
A new monoclonal antibody called Isatuximab is advancing through clinical trials and is getting closer to FDA approval. This antibody targets CD38. Learn more from Dr. Ravi Vij of Washington University as he discusses the findings from recent clinical trials, how this drug will be used in the clinc and how it is different from other monoclonal ...…
 
Nearly 13000 women are diagnosed with cervical cancer in the United States each year and about 68% of all invasive cervical cancer cases diagnosed involve women of childbearing age. Advanced treatments available today allow women to live longer but the same treatments impact their fertility negatively, decreasing their quality of life severely. ...…
 
Major progress is being made in the field of multiple myeloma including a vast array of immunotherapy options. Learn about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-comin ...…
 
The treatment paradigm for myeloma patients has changed in the last decade with important advancements such as proteasome inhibitors, IMiDS, antibodies and risk-adapted maintenance. How a patient responds to therapy can be used to determine how long the maintenance or follow-up therapy should be. This is called risk-adapted therapy and personal ...…
 
How clinical trials can help physicians and researchers better care for and learn from people with cancer. Guest: Monica Bertagnolli, MD, president of the American Society of Clinical Oncology (ASCO). Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.…
 
Polycystic ovary syndrome (PCOS) is a health condition that affects 1 in 10 women of childbearing age. Women with PCOS have a hormonal imbalance and metabolism problems that may lead to obesity, cardiovascular disease, type 2 diabetes, infertility, endometrial cancer and more. In the absence of a complete cure, efficient management of the condi ...…
 
Testing Your Individual Myeloma Tumor Against Available Myeloma Therapies Each myeloma patient's tumor is unique and can change over time. Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the testing of over 50 myeloma treatment combinations against your specific tumor (including your bone marrow microenvironment) t ...…
 
Targeting CD24 to Eliminate Myeloma Stem Cells Myeloma stem cells (or early progenitor cells before they become plasma cells) may not be killed with current myeloma therapies and could be the cause of relapse. Dr. Zhan has identified the presence of CD24 as a strong candidate as a cancer stem cell marker and believes that high CD24 levels lead ...…
 
Biomarkers in Lung Cancer: Targeting the Right Patient With the Right Therapy
 
The 15 most interesting abstracts to be presented at the 2018 meeting of the American Society of Hematology (ASH), according to Dr. John Leonard. Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
 
Why do some multiple myeloma patients relapse early after stem cell transplant while others stay in remission for many years? The immune system may be a key factor. David Chung, MD, PhD of Memorial Sloan Kettering Cancer Center was recently selected as a Myeloma Crowd Research Initiative (MCRI) award recipient. The goal of the MCRI is to help o ...…
 
Eat more and pile on weight. Eat less and loose weight. Or is it that simple? HOW and WHAT should we eat to stay fit and away from obesity? A talk with investigative science & health Journalist and co-founder of the non-profit Nutrition Science Initiative (NuSI.org) Gary Taubes, to discuss the relationship of Obesity & Calories, the current sta ...…
 
Of the nearly 100,000 people waiting for a kidney transplant in the U.S., many will never get one. Meanwhile, hundreds of Hepatitis C infected organs are discarded because of the infection. The doctors at University of Pennsylvania connected these events and led a study that successfully showed that it is possible to transplant Hepatitis C infe ...…
 
What all men and their loved ones should know about prostate cancer screening. Guest: Jim Hu, MD, MPH, urologic oncologist and director of the Lefrak Center for Robotic Surgery at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and New ...…
 
In the World Series and the world of baseball, a strategy for success means planning ahead - doing everything you can to come out a winner. In the world of multiple myeloma, that means being your best advocate and coming up with your Most Valuable Plan. Which doctor will you choose, what treatments will you receive and in what order? Having a g ...…
 
African Americans are twice as likely to be diagnosed with the rare blood cancer called multiple myeloma than white Americans and other ethnicities. Why is this and what can we do to ensure that this population obtains their very best care? Learn more about the genetics, younger diagnosis and other unique features for these patients and what we ...…
 
Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Knowledge To Improve Outcomes
 
Best Practices for Use of Proteasome Inhibitors in the Treatment of Relapsed/Refractory Multiple Myeloma
 
Stand Up To Cancer has announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease. The team will be led by Irene Ghobrial, MD at Dana-Farber Cance ...…
 
The latest advances in caring for people with pancreatic cancer. Guest: Allyson Ocean, MD, gastrointestinal oncologist and pancreatic cancer expert at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.…
 
At last year's ASH meeting, there was excitement around a new antibody drug conjugate targeting a protein called BCMA from Glaxo Smith Klein. Results from their Phase I study showed that patients who had relapsed immunomodulators (like Revlimid), proteasome inhibitors (like Velcade) and even monoclonal antibodies (like daratumumab), responded w ...…
 
How specific gene mutations can enable prediction of acute myeloid leukemia (AML) up to a decade prior to disease development. Guest: Pinkal Desai, MD, hematologist and medical oncologist at the Weill Cornell Medicine and NewYork-Presbyterian Hospital Leukemia Program. Host: John Leonard, MD, world-renowned hematologist and medical oncologist a ...…
 
A mother’s immune system is altered during pregnancy so that the fetus is not rejected by her body and is allowed to grow. When this balance goes awry, the immune system may become the cause of a miscarriage or multiple miscarriages. We are talking to Dr. Jeffrey Braverman, a world leader in reproductive immunology, about the role of immune sys ...…
 
Multiple Myeloma is the second most common cancer of the blood and is largely incurable. A recent study has found that a specific gene mutation can increase the risk of developing myeloma six to nine fold. The lead author of the study and Professor of Medicine and Genetic Medicine at Weill Cornell, Dr. Steven M. Lipkin is talking to the panel o ...…
 
The functionality and significance of scalp-cooling technology. Guest: Tessa Cigler, MD, MPH, Clinical Director of the Breast Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.…
 
The importance of patient advocacy and how those affected by cancer can make their voices heard. Guest: Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.…
 
Over 10 million people in the US have a neurodegenerative condition. Half of these people have Alzheimer's Disease making it the most common neurodegenerative condition in the US. Among the remaining, a large population suffer from frontotemporal dementia (FTD). However, FTD and Alzheimer's are very often misdiagnosed for eachother and even the ...…
 
The myeloma landscape is rapidly changing with many new advancements. Paul Richardson, MD of the Dana Farber Cancer Institute joins Myeloma Crowd Radio to share recent updates from major summer meetings including the American Society of Clinical Oncology and European Hematology Association meeting and several others. Thanks to our episode spons ...…
 
How do multiple myeloma patients get into clinical trials? Especially those using popular new science like CAR T therapy? Brian McMahon, founder of SparkCures shares tips and tricks to get into these trials. Brian is the founder of SparkCures, a multiple myeloma clinical trial finder tool that simplifies the process. Brian shares his experience ...…
 
The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient or belong to high-risk group, treatment paradigms are getting better. We are talking to Dr. Mateos on Myeloma research and treatment modalities discussed and presented at the recently conclud ...…
 
How one patient, diagnosed with lymphoma at age 29, coped with the lifestyle changes brought about by cancer. Guest: CC Webster, Hodgkin lymphoma survivor. Host: John Leonard, M.D., world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
 
An expert synopsis of the hottest topics in cancer research and treatment, including precision medicine, immunotherapy, and liquid biopsies to capture circulating tumor DNA. Guest: David Nanus, M.D., Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: John Leonard, M.D., world-renowned hem ...…
 
Why anxiety management is so important for all those affected by cancer, plus actionable coping strategies. Guest: Kelly Trevino, Ph.D., clinical psychologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: John Leonard, M.D., world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyteria ...…
 
An exploration of CAR T-cell therapy and its role in the future of cancer treatment. Guest: David G. Maloney, M.D., Ph. D., medical director of cellular immunotherapy at the Fred Hutchinson Cancer Research Center. Host: John Leonard, M.D., world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hosp ...…
 
In December 2017, the FDA approved a DNA altering medication that can reverse an inherited form of progressive blindness. Luxturna is a gene therapy which can treat a condition called Leber's Congenital Amaurosis (LCA) wherein people have inherited two faulty copies of the RPE65 gene. The therapy replaces those faulty genes with normal versions ...…
 
Improving Treatment Monitoring and Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
 
Many multiple myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Researchers found that expression of MUC20 could help predict how sensitive or resistant patients would be to proteasome inhibitors and found that MUC20 protein could be potentially impacted by an already FDA-approved drug of ...…
 
A new tool for multiple myeloma patients is coming in June! Join us as we discuss the Myeloma Crowd's new initiative called HealthTree with Rafael Fonseca, MD of the Mayo Clinic in Scottsdale. HealthTree will help myeloma patients understand their personally relevant treatment options, find clinical trials, track lab data and help accelerate re ...…
 
Locally Advanced BCC: Selecting the Right Option to Optimise Outcomes in Your Patients
 
Myeloma patients are definitely living longer. A decade ago the median survival was 3 to 4 years, while now it is in the range of 8 to 10 years. With all the new drugs and treatments that have been approved, it is possible to control the disease for a longer period of time. We are talking to Dr. Shaji Kumar to explore the treatment potential of ...…
 
Improving the Long-Term Treatment Plan for Patients With Metastatic Pancreatic Cancer: Insights From San Francisco
 
Research has shown that our mental state affects the outcomes of treatment in all disease conditions, including infertility, where it may decrease the chances of conception. Couples dealing with infertility go through immense stress, often times severe depression, as the follow up and treatment of infertility itself may cause anxiety and depres ...…
 
Google login Twitter login Classic login